CLVS - Clovis Oncology, Inc.
| Previous Close | 9.71 |
| Open | 9.67 |
| Bid | 0.00 x 1100 |
| Ask | 9.93 x 3100 |
| Day's Range | 9.00 - 9.89 |
| 52 Week Range | 2.93 - 32.05 |
| Volume | 6,750,252 |
| Avg. Volume | 10,583,027 |
| Market Cap | 685.277M |
| Beta (5Y Monthly) | 3.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.50 |
| Earnings Date | Feb 23, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.03 |
- Zacks
Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Clovis (CLVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
- Business Wire
Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2019 financial results on Monday, February 24, 2020, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail.
- Business Wire
Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 10:30 a.m. Eastern Standard Time. The conference will be held at the Lotte New York Palace in New York City.
- Benzinga
4 Stocks Looking Higher During Earnings Season
Clovis Oncology, Inc. (NASDAQ: CLVS) popped 90 cents, or more than 10%, to $9.73 on 11.7 million shares Wednesday on no news. 3D Systems Corporation (NYSE: DDD) climbed 63 cents, or 5.3%, to $12.34 on 2.9 million shares Wednesday. Wednesday's move broke the stock out of a month-long wedge formation, and next resistance for the stock, which has nearly doubled in 5 months, is at $14.25.
- MarketWatch
Four stocks to watch this week include Clovis Oncology and 3D Systems
Harry Boxer on stocks that are at, or near, key breakout points.
- Zacks
Is a Beat in the Cards for Humana's (HUM) Earnings in Q4?
Humana's (HUM) fourth-quarter results are likely to reflect lower membership, partly offset by higher revenues.
- Business Wire
Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France
Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France
- Simply Wall St.
Have Insiders Been Buying Clovis Oncology, Inc. (NASDAQ:CLVS) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
- Zacks
Acceleron (XLRN) Up on Success of PAH Drug in Phase II Study
Acceleron (XLRN) stock surges as sotatercept meets primary and secondary endpoints in a phase II study in patients with pulmonary arterial hypertension.
- American City Business Journals
You can bring your skis to this Bay Area tech bank's new downtown Denver office
Santa Clara, California-based Silicon Valley Bank (Nasdaq: SIVB) has moved its Colorado loan production office from Broomfield to the Tabor Center at 1200 17th St. in downtown Denver. Josh Dorsey, managing director at Silicon Valley Bank who oversees the Colorado market, said the bank hopes to create a welcoming space for its clients to come visit. “When we built out this office, we had our community and clients in mind,” Dorsey said.
- Zacks
Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon
A low-key week for the biotech sector with a few pipeline and regulatory updates.
- Zacks
Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review
Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.
- Investor's Business Daily
Why This Highly Rated Biotech Stock Jumped As High As 26%
Shares of Clovis Oncology jumped in higher-than-average volume on Wednesday after U.S. regulators accepted the biotech company's application for a prostate cancer treatment.
- MarketWatch
Clovis Oncology's stock soars after FDA accepts sNDA for prostate cancer treatment
Shares of Clovis Oncology Inc. soared 22% in very active premarket trading Wednesday, after the biopharmaceutical company said the supplemental new drug application (sNDA) for its prostate cancer treatment Rubraca has been granted priority review status by the Food and Drug Administration. Trading volume swelled to over 2.9 million shares, compared with the full-day average of 10.7 million shares. "Recently presented data suggests that Rubraca may play a meaningful role in the treatment of patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer, and this filing represents an important milestone for Clovis as it brings us one step closer to potentially making this valuable therapy available," said Chief Executive Patrick Mahaffy. "We are encouraged by the FDA's decision to grant priority review to the Rubraca application, which focuses on eligible patients with advanced prostate cancer, for whom new treatment options are very much needed." The stock has nearly tripled (up 177.7%) over the past three months through Tuesday, while the iShares Nasdaq Biotechnology ETF has advanced 18.2% and the S&P 500 has gained 9.6%.
- Business Wire
Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer
Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer
- Zacks
Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020
Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020
- Business Wire
Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited revenues for the fourth quarter and full year ended December 31, 2019. The financial information presented in this news release may be adjusted as a result of completion of customary quarterly review and audit procedures.
- Business Wire
Clovis Oncology Announces Debt Refinancing Transaction
Clovis Oncology, Inc. (NASDAQ: CLVS) (the "Company") announced today that on January 6, 2020 it priced a registered direct offering (the "Share Offering") of an aggregate of 17,777,679 shares (the "Shares") of its common stock at a price of $9.25 per share to a limited number of holders (the "Holders") of its 4.50% Convertible Senior Notes due 2024 (the "2024 Notes"). The Company intends to use the proceeds of the Share Offering to repurchase from such Holders an aggregate of $123,417,000 principal amount of its 2024 Notes (the "Note Repurchase", and collectively with the Share Offering, the "Transactions") in privately negotiated transactions. J.P. Morgan and BofA Securities acted as the exclusive agents to the Company in connection with the Transactions.
- Zacks
Implied Volatility Surging for Clovis (CLVS) Stock Options
Investors need to pay close attention to Clovis (CLVS) stock based on the movements in the options market lately.
- Benzinga
Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus
Biotech stocks advanced in the penultimate week of the year, and the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) is on track to end the year with gains in excess of 25%. The previous week saw FDA ...
- Zacks
FDA Accepts Immunomedics' BLA Refiling for Breast Cancer Drug
The FDA accepts Immunomedics' (IMMU) BLA resubmission for sacituzumab govitecan to treat patients with metastatic triple-negative breast cancer, having received at least two prior therapies.
